Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A head-to-head clinical phase 1b trial of the APG777 in combination with APG990 (APG279 program) against Dupixent in moderate-to-severe AD of APG279

Next Previous
Search
Trial Profile

A head-to-head clinical phase 1b trial of the APG777 in combination with APG990 (APG279 program) against Dupixent in moderate-to-severe AD of APG279

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APG-279 (Primary) ; Dupilumab
  • Indications Atopic dermatitis
  • Focus Adverse reactions

Most Recent Events

  • 03 Mar 2025 According to an Apogee Therapeutics media release, data expected in the second half of 2026.
  • 28 Feb 2025 trial event According to an Apogee Therapeutics media release, the Company will host a conference call and webcast at 8:30am ET to discuss the results and plans for its combination approach for APG777 + APG990.
  • 19 Aug 2024 According to an Apogee Therapeutics media release, pending positive results from the Phase 1 clinical trial and following submission of an Investigational New Drug application or foreign equivalent, company plans to initiate the first clinical trial of the APG777 and APG990 combination in 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top